Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2Classical hematology 2

Conditions

Myeloproliferative Disorders 2Anemia 2Primary Myelofibrosis 1Myelodysplastic Syndromes 1

Interventions

Cyclophosphamide 8Whole-Body Irradiation 6fludarabine 5fludarabine phosphate 4Tacrolimus 4Mycophenolic Acid 4Melphalan 4Busulfan 3luspatercept 2Vorinostat 2Thiotepa 2Sirolimus 2Peripheral Blood Stem Cell Transplantation 2Lenalidomide 2Granulocyte Colony-Stimulating Factor 2Biopsy 2Azacitidine 2AP 1903 reagent 2venetoclax 1ribociclib 1palbociclib 1olaparib 1ibrutinib 1hetrombopag 1edoxaban 1decitabine and cedazuridine drug combination 1apixaban 1acalabrutinib 1abemaciclib 1Valganciclovir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × luspatercept × Classical hematology × Clear all
NCT05732961 2026-05-05

Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
6 enrolled
Classical hematologyMyeloid

Anemia, Myelodysplastic Syndromes, Myeloproliferative Disorders

NCT04717414 2025-07-10

INDEPENDENCE

Celgene

Phase 3 Active not recruiting
313 enrolled
Classical hematologyMyeloid

Anemia, Myeloproliferative Disorders, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡